Literature DB >> 16098075

Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation.

B Kampmann1, D Cubitt, T Walls, P Naik, M Depala, S Samarasinghe, D Robson, A Hassan, K Rao, H Gaspar, G Davies, A Jones, C Cale, K Gilmour, M Real, M Foo, N Bennett-Rees, A Hewitt, P Amrolia, Paul Veys.   

Abstract

Adenovirus (AdV) infections are a frequent cause of morbidity and mortality following allogeneic stem cell transplantation (SCT), and disseminated infection is associated with high mortality, particularly in paediatric SCT. Here, we describe an approach to reduce mortality from adenoviraemia by combining prospective monitoring for the occurrence of adenoviraemia using a sensitive polymerase chain reaction method, early antiviral therapy and prompt withdrawal of immunosuppression. A total of 155 consecutive paediatric SCT procedures were prospectively monitored, of which 113 (73%) transplants involved donors other than matched siblings and 126 (83%) employed T-cell depletion. Adenoviraemia was detected in 26/155 (17%) transplants and developed exclusively in patients who had received T-cell-depleted grafts. Withdrawal of immunosuppression coupled with early antiviral therapy led to resolution of adenoviraemia in 19/26 (81%) patients with only five patients succumbing to disseminate AdV infection. Survival from adenoviraemia was associated with lymphocyte recovery to above 0.3x10(9)/l. Mortality was closely linked with the absence of lymphocyte recovery because of profound T-cell depletion of the graft with CD34+ magnetic-activated cell sorting. Mortality from disseminated AdV infection was 5/26 (19%) in this study, which is significantly lower than previously reported.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098075     DOI: 10.1111/j.1365-2141.2005.05649.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  26 in total

1.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

Review 2.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  Adenovirus: current epidemiology and emerging approaches to prevention and treatment.

Authors:  Uriel Sandkovsky; Luciano Vargas; Diana F Florescu
Journal:  Curr Infect Dis Rep       Date:  2014-08       Impact factor: 3.725

Review 4.  Immunotherapy for opportunistic infections: Current status and future perspectives.

Authors:  Shigeo Fuji; Jürgen Löffler; Hermann Einsele; Markus Kapp
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

5.  Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients.

Authors:  Diana F Florescu; Steven A Pergam; Michael N Neely; Fang Qiu; Christine Johnston; SingSing Way; Jane Sande; Deborah A Lewinsohn; Judith A Guzman-Cottrill; Michael L Graham; Genovefa Papanicolaou; Joanne Kurtzberg; Joseph Rigdon; Wendy Painter; Herve Mommeja-Marin; Randall Lanier; Maggie Anderson; Charles van der Horst
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-29       Impact factor: 5.742

6.  Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.

Authors:  Maria A Thomas; Jacqueline F Spencer; Karoly Toth; John E Sagartz; Nancy J Phillips; William S M Wold
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

Review 7.  Adenoviruses in immunocompromised hosts.

Authors:  Marcela Echavarría
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

8.  Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X.

Authors:  Angela C Bradshaw; Alan L Parker; Margaret R Duffy; Lynda Coughlan; Nico van Rooijen; Veli-Matti Kähäri; Stuart A Nicklin; Andrew H Baker
Journal:  PLoS Pathog       Date:  2010-10-07       Impact factor: 6.823

Review 9.  Advancement of pediatric blood and marrow transplantation research in North America: priorities of the Pediatric Blood and Marrow Transplant Consortium.

Authors:  Michael A Pulsipher; Edwin M Horwitz; Ann E Haight; Richard Kadota; Allen R Chen; Haydar Frangoul; Laurence J N Cooper; David A Jacobsohn; Rakesh K Goyal; David Mitchell; Michael L Nieder; Gregory Yanik; Morton J Cowan; Sandeep Soni; Sharon Gardner; Shalini Shenoy; Douglas Taylor; Mitchell Cairo; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-14       Impact factor: 5.742

10.  Unique sequence features of the Human adenovirus 31 complete genomic sequence are conserved in clinical isolates.

Authors:  Soeren Hofmayer; Ijad Madisch; Sebastian Darr; Fabienne Rehren; Albert Heim
Journal:  BMC Genomics       Date:  2009-11-25       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.